Although initial FAERS reports raised concerns regarding potential AKI risk, current high-quality evidence from well-conducted RCTs and meta-analyses strongly supports a renoprotective effect of SGLT2 inhibitors across various high-risk populations, including those with T2DM, HF, and CKD. Here, SLC5A2 is linked to chronic kidney disease.